Galderma stands out as one of the few forces capable of inventing, developing and bringing to market novel dermatological solutions for patient needs and consumer benefits. Our best-in-class R&D pipeline features ambitious, differentiated projects that target strategic therapeutic areas across Aesthetics, Consumer Care and Prescription medicine.
In addition to our in-house resources and capabilities, we are a partner of choice for academic and industrial research collaboration around the world. Collaborations enable access to complementary perspectives, different areas of expertise, emerging technologies and disruptive concepts. They extend our ability to serve the needs of healthcare professionals and patients, helping to advance global health.
NEMOLIZUMAB
A first-in-class investigational monoclonal antibody that blocks signaling of IL-31, a cytokine that is not only acting on pruritus but also plays a key role in skin inflammation in atopic dermatitis and prurigo nodularis, two skin conditions associated with high burden of disease.
RELABOTULINUMTOXIN-A
A proprietary novel, ready-to-use, liquid formulation of investigational botulinum toxin, for the treatment of glabellar lines and lateral canthal lines.
CETAPHIL PORTFOLIO EXPANSION
Continuously developing new line-ups to further extend the Cetaphil range and meet the needs of specific skin conditions.
